Advertisement
Table 3 The inter-relationship between clinico-pathological characteristics and lymphatic invasion (LVI D2-40 ) in patients with primary operable invasive ductal breast cancer
| All patients (n = 360) | LVID2–40-ve | LVID2–40+ve | ( P-value) |
|---|---|---|---|
| n = 233 (65%) | n = 127 (35%) | ||
| Age (≤50/ >50 years) | 69/164 | 56/71 | 0.006 |
| Size (≤20/ 21-50/ >50 mm) | 129/97/7 | 56/65/6 | 0.038 |
| Grade (I / II / III) | 156/73/13 | 56/53/21 | <0.001 |
| Involved lymph node (0/1-3/ >3) | 153/80 | 53/74 | <0.001 |
| ER status (no/yes) | 102/131 | 69/58 | 0.056 |
| PR status (no/yes) | 118/115 | 76/51 | 0.095 |
| HER2 status (no/yes) | 193/40 | 96/31 | 0.099 |
| Endocrine therapy (no/yes) | 168/62 | 104/19 | 0.014 |
| Chemotherapy (no/yes) | 150/80 | 59/64 | 0.002 |
| Tumour recurrence (no/local/distant/both) | 199/5/28/1 | 72/12/39/4 | <0.001 |
| Alive/cancer death/non cancer death | 141/39/53 | 48/58/21 | 0.059 |
| Cancer specific survival (months)a | 186(177–194) | 134(120–149) | <0.001 |
| Node-negative disease (n = 206) | n = 153 (74%) | n = 53 (26%) | |
| Age (≤50/ >50 years) | 42/111 | 25/28 | 0.008 |
| Size (≤20/ 21-50/ >50 mm) | 96/55/2 | 24/27/2 | 0.019 |
| Grade (I / II / III) | 33/53/67 | 1/20/32 | 0.002 |
| ER status (no/yes) | 32/48 | 40/34 | 0.082 |
| PR status (no/yes) | 38/42 | 43/31 | 0.189 |
| HER2 status (no/yes) | 130/23 | 38/15 | 0.032 |
| Endocrine therapy (no/yes) | 106/46 | 43/9 | 0.070 |
| Chemotherapy (no/yes) | 111/41 | 31/21 | 0.070 |
| Tumour recurrence (no/local/distant/both) | 137/4/11/1 | 33/4/14/2 | <0.001 |
| Alive/cancer death/non cancer death | 99/18/36 | 25/17/11 | 0.266 |
| Cancer specific survival (months)a | 198(190–206) | 153(131–174) | 0.001 |
| Triple-negative patients (n = 120) | n = 74(62%) | 46(38%) | |
| Age (≤50/ >50 years) | 26/48 | 24/22 | 0.064 |
| Size (≤20/ 21-50/ >50 mm) | 42/28/4 | 21/23/2 | 0.367 |
| Grade (I / II / III) | 1/13/60 | 0/8/38 | 0.712 |
| Involved lymph node (-ve/+ve) | 52/22 | 18/28 | 0.001 |
| Endocrine therapy (no/yes) | 65/9 | 42/3 | 0.336 |
| Chemotherapy (no/yes) | 36/38 | 15/30 | 0.103 |
| Tumour recurrence (no/local/distant) | 64/0/10 | 24/3/19 | <0.001 |
| Alive/cancer death/non cancer death | 48/13/13 | 18/24/4 | 0.217 |
| Cancer specific survival (months)a | 176(161–192) | 122(96–147) | <0.001 |
